Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study
In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluat...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-09, Vol.16 (9), p.e0257551 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | e0257551 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Ishikawa, Masashi Takashima, Atsuo Nagata, Yusuke Sawada, Ryoichi Aoki, Masahiko Imazeki, Hiroshi Hirano, Hidekazu Shoji, Hirokazu Honma, Yoshitaka Iwasa, Satoru Okita, Natsuko Kato, Ken Saruta, Masayuki Boku, Narikazu |
| description | In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).
The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.
Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR |
| doi_str_mv | 10.1371/journal.pone.0257551 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2576318614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A676619622</galeid><doaj_id>oai_doaj_org_article_80f72f9eb44243b8941b7eac292aa720</doaj_id><sourcerecordid>A676619622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c641t-c94f1e053b84bb5ef2067a4a7d29d06380db116c0f9afd967219c03bd8fd693b3</originalsourceid><addsrcrecordid>eNqNk81u1DAQxyMEoqXwBggsISE47BI7jpNwQFpVfFSqVAkKV2viTBKvnHhrO1v2WXhZ3N1t1UU9oBwST37zny9Pkryk6ZxmBf2wtJMbwcxXdsR5yvIiz-mj5JhWGZsJlmaP730fJc-8X6ZpnpVCPE2OMp7nVUnL4-TP5TRYRzpnr0NPHAQkzeT02BGHM9WDMTh2SFSPgw09OlhtyLWO6MrhWtvJmw2ZPDYEOhyDJ-CJB7OOJxIcQhiilbQxwoABfICgFVHWWIcqgCEKRoXuI1nEcMFZv4pmvUbiw9RsnidPWjAeX-zfJ8nPL58vT7_Nzi--np0uzmdKcBpmquItxVhbXfK6zrFlqSiAQ9GwqklFVqZNTalQaVtB21SiYLRSaVY3ZduIKquzk-T1TndlrJf7vnoZWyoyWgrKI3G2IxoLS7lyegC3kRa03Bqs6yS4WJpBWaZtwdoKa84ZjylVnNYFgmIVAyjiLE6ST_toUz1go2KDHJgD0cM_o-5lZ9ey5IIV22Te7QWcvZrQBzlor9AYGDEOZJu3yBmneUTf_IM-XN2e6iAWoMfWxrjqRlQuRNSilWAsUvMHqPg0OGgVL2Gro_3A4f2BQ2QC_g4dTN7Lsx_f_5-9-HXIvr3H9ggm9N6aKWg7-kOQ70AVb5Z32N41mabyZoduuyFvdkjudyi6vbo_oDun26XJ_gJIGBqX</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576318614</pqid></control><display><type>article</type><title>Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ishikawa, Masashi ; Takashima, Atsuo ; Nagata, Yusuke ; Sawada, Ryoichi ; Aoki, Masahiko ; Imazeki, Hiroshi ; Hirano, Hidekazu ; Shoji, Hirokazu ; Honma, Yoshitaka ; Iwasa, Satoru ; Okita, Natsuko ; Kato, Ken ; Saruta, Masayuki ; Boku, Narikazu</creator><contributor>Cecchin, Erika</contributor><creatorcontrib>Ishikawa, Masashi ; Takashima, Atsuo ; Nagata, Yusuke ; Sawada, Ryoichi ; Aoki, Masahiko ; Imazeki, Hiroshi ; Hirano, Hidekazu ; Shoji, Hirokazu ; Honma, Yoshitaka ; Iwasa, Satoru ; Okita, Natsuko ; Kato, Ken ; Saruta, Masayuki ; Boku, Narikazu ; Cecchin, Erika</creatorcontrib><description>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).
The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.
Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively.
We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0257551</identifier><identifier>PMID: 34559818</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Anticancer properties ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Complications and side effects ; Disease control ; Drug Therapy - methods ; Drugs ; Female ; Gastroenterology ; Growth ; Growth rate ; Health services ; Hepatology ; Hospitals ; Humans ; Internal medicine ; Irinotecan ; Male ; Medical imaging ; Medical prognosis ; Medicine ; Medicine and Health Sciences ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Metastasis - drug therapy ; Oncology ; Oxaliplatin ; Patient outcomes ; Patients ; Research and Analysis Methods ; Retrospective Studies ; Shrinkage ; Survival ; Tumors</subject><ispartof>PloS one, 2021-09, Vol.16 (9), p.e0257551</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Ishikawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Ishikawa et al 2021 Ishikawa et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c641t-c94f1e053b84bb5ef2067a4a7d29d06380db116c0f9afd967219c03bd8fd693b3</cites><orcidid>0000-0002-8456-1248 ; 0000-0002-1733-5072 ; 0000-0001-6631-3913</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462714/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462714/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34559818$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Cecchin, Erika</contributor><creatorcontrib>Ishikawa, Masashi</creatorcontrib><creatorcontrib>Takashima, Atsuo</creatorcontrib><creatorcontrib>Nagata, Yusuke</creatorcontrib><creatorcontrib>Sawada, Ryoichi</creatorcontrib><creatorcontrib>Aoki, Masahiko</creatorcontrib><creatorcontrib>Imazeki, Hiroshi</creatorcontrib><creatorcontrib>Hirano, Hidekazu</creatorcontrib><creatorcontrib>Shoji, Hirokazu</creatorcontrib><creatorcontrib>Honma, Yoshitaka</creatorcontrib><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Okita, Natsuko</creatorcontrib><creatorcontrib>Kato, Ken</creatorcontrib><creatorcontrib>Saruta, Masayuki</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><title>Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).
The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.
Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively.
We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.</description><subject>Anticancer properties</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Complications and side effects</subject><subject>Disease control</subject><subject>Drug Therapy - methods</subject><subject>Drugs</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Growth</subject><subject>Growth rate</subject><subject>Health services</subject><subject>Hepatology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Irinotecan</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - drug therapy</subject><subject>Oncology</subject><subject>Oxaliplatin</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Research and Analysis Methods</subject><subject>Retrospective Studies</subject><subject>Shrinkage</subject><subject>Survival</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk81u1DAQxyMEoqXwBggsISE47BI7jpNwQFpVfFSqVAkKV2viTBKvnHhrO1v2WXhZ3N1t1UU9oBwST37zny9Pkryk6ZxmBf2wtJMbwcxXdsR5yvIiz-mj5JhWGZsJlmaP730fJc-8X6ZpnpVCPE2OMp7nVUnL4-TP5TRYRzpnr0NPHAQkzeT02BGHM9WDMTh2SFSPgw09OlhtyLWO6MrhWtvJmw2ZPDYEOhyDJ-CJB7OOJxIcQhiilbQxwoABfICgFVHWWIcqgCEKRoXuI1nEcMFZv4pmvUbiw9RsnidPWjAeX-zfJ8nPL58vT7_Nzi--np0uzmdKcBpmquItxVhbXfK6zrFlqSiAQ9GwqklFVqZNTalQaVtB21SiYLRSaVY3ZduIKquzk-T1TndlrJf7vnoZWyoyWgrKI3G2IxoLS7lyegC3kRa03Bqs6yS4WJpBWaZtwdoKa84ZjylVnNYFgmIVAyjiLE6ST_toUz1go2KDHJgD0cM_o-5lZ9ey5IIV22Te7QWcvZrQBzlor9AYGDEOZJu3yBmneUTf_IM-XN2e6iAWoMfWxrjqRlQuRNSilWAsUvMHqPg0OGgVL2Gro_3A4f2BQ2QC_g4dTN7Lsx_f_5-9-HXIvr3H9ggm9N6aKWg7-kOQ70AVb5Z32N41mabyZoduuyFvdkjudyi6vbo_oDun26XJ_gJIGBqX</recordid><startdate>20210924</startdate><enddate>20210924</enddate><creator>Ishikawa, Masashi</creator><creator>Takashima, Atsuo</creator><creator>Nagata, Yusuke</creator><creator>Sawada, Ryoichi</creator><creator>Aoki, Masahiko</creator><creator>Imazeki, Hiroshi</creator><creator>Hirano, Hidekazu</creator><creator>Shoji, Hirokazu</creator><creator>Honma, Yoshitaka</creator><creator>Iwasa, Satoru</creator><creator>Okita, Natsuko</creator><creator>Kato, Ken</creator><creator>Saruta, Masayuki</creator><creator>Boku, Narikazu</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8456-1248</orcidid><orcidid>https://orcid.org/0000-0002-1733-5072</orcidid><orcidid>https://orcid.org/0000-0001-6631-3913</orcidid></search><sort><creationdate>20210924</creationdate><title>Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study</title><author>Ishikawa, Masashi ; Takashima, Atsuo ; Nagata, Yusuke ; Sawada, Ryoichi ; Aoki, Masahiko ; Imazeki, Hiroshi ; Hirano, Hidekazu ; Shoji, Hirokazu ; Honma, Yoshitaka ; Iwasa, Satoru ; Okita, Natsuko ; Kato, Ken ; Saruta, Masayuki ; Boku, Narikazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c641t-c94f1e053b84bb5ef2067a4a7d29d06380db116c0f9afd967219c03bd8fd693b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anticancer properties</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Complications and side effects</topic><topic>Disease control</topic><topic>Drug Therapy - methods</topic><topic>Drugs</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Growth</topic><topic>Growth rate</topic><topic>Health services</topic><topic>Hepatology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Irinotecan</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - drug therapy</topic><topic>Oncology</topic><topic>Oxaliplatin</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Research and Analysis Methods</topic><topic>Retrospective Studies</topic><topic>Shrinkage</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishikawa, Masashi</creatorcontrib><creatorcontrib>Takashima, Atsuo</creatorcontrib><creatorcontrib>Nagata, Yusuke</creatorcontrib><creatorcontrib>Sawada, Ryoichi</creatorcontrib><creatorcontrib>Aoki, Masahiko</creatorcontrib><creatorcontrib>Imazeki, Hiroshi</creatorcontrib><creatorcontrib>Hirano, Hidekazu</creatorcontrib><creatorcontrib>Shoji, Hirokazu</creatorcontrib><creatorcontrib>Honma, Yoshitaka</creatorcontrib><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Okita, Natsuko</creatorcontrib><creatorcontrib>Kato, Ken</creatorcontrib><creatorcontrib>Saruta, Masayuki</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishikawa, Masashi</au><au>Takashima, Atsuo</au><au>Nagata, Yusuke</au><au>Sawada, Ryoichi</au><au>Aoki, Masahiko</au><au>Imazeki, Hiroshi</au><au>Hirano, Hidekazu</au><au>Shoji, Hirokazu</au><au>Honma, Yoshitaka</au><au>Iwasa, Satoru</au><au>Okita, Natsuko</au><au>Kato, Ken</au><au>Saruta, Masayuki</au><au>Boku, Narikazu</au><au>Cecchin, Erika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-09-24</date><risdate>2021</risdate><volume>16</volume><issue>9</issue><spage>e0257551</spage><pages>e0257551-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR).
The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx.
Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively.
We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34559818</pmid><doi>10.1371/journal.pone.0257551</doi><tpages>e0257551</tpages><orcidid>https://orcid.org/0000-0002-8456-1248</orcidid><orcidid>https://orcid.org/0000-0002-1733-5072</orcidid><orcidid>https://orcid.org/0000-0001-6631-3913</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-09, Vol.16 (9), p.e0257551 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2576318614 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Anticancer properties Antineoplastic Agents - therapeutic use Cancer Cancer therapies Care and treatment Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Complications and side effects Disease control Drug Therapy - methods Drugs Female Gastroenterology Growth Growth rate Health services Hepatology Hospitals Humans Internal medicine Irinotecan Male Medical imaging Medical prognosis Medicine Medicine and Health Sciences Metastases Metastasis Middle Aged Neoplasm Metastasis - drug therapy Oncology Oxaliplatin Patient outcomes Patients Research and Analysis Methods Retrospective Studies Shrinkage Survival Tumors |
| title | Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A54%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20growth%20rate%20during%20re-challenge%20chemotherapy%20with%20previously%20used%20agents%20as%20salvage%20treatment%20for%20metastatic%20colorectal%20cancer:%20A%20retrospective%20study&rft.jtitle=PloS%20one&rft.au=Ishikawa,%20Masashi&rft.date=2021-09-24&rft.volume=16&rft.issue=9&rft.spage=e0257551&rft.pages=e0257551-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0257551&rft_dat=%3Cgale_plos_%3EA676619622%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576318614&rft_id=info:pmid/34559818&rft_galeid=A676619622&rft_doaj_id=oai_doaj_org_article_80f72f9eb44243b8941b7eac292aa720&rfr_iscdi=true |